Sandoz Expects Imminent US Pegfilgrastim Action
Seven Months Have Passed Since Refiling With FDA
Sandoz chief Richard Saynor remains confident in the firm’s US pegfilgrastim filing, even though it has been with the FDA for more than six months.
You may also be interested in...
Sandoz has finally received a much-awaited FDA approval for its pegfilgrastim biosimilar, Ziextenzo, which will be launched in the US “as soon as possible this year.”
Launching its Kanjinti and Mvasi trastuzumab and bevacizumab biosimilars ‘at risk’ in July generated third-quarter sales of $81m for Amgen, contributing nearly half of global biosimilar turnover of $173m.
Polpharma and Sandoz have stuck a global licensing deal that gives the Novartis subsidiary rights to market the Polish firm’s biosimilar natalizumab rival to Biogen’s Tysabri.